Search
Search Results
-
Clinical outcomes up to 9 years after [18F]flutemetamol amyloid-PET in a symptomatic memory clinic population
BackgroundPrevious studies demonstrated increases in diagnostic confidence and change in patient management after amyloid-PET. However, studies...
-
Amyloid PET Imaging: Standard Procedures and Semiquantification
Amyloid plaques are a neuropathologic hallmark of Alzheimer’s disease (AD), which can be imaged through positron emission tomography (PET) technology...
-
Plasma amyloid-beta oligomer is related to subjective cognitive decline and brain amyloid status
BackgroundSubjective cognitive decline (SCD) is a target for Alzheimer’s disease prediction. Plasma amyloid-beta oligomer (AβO), the pathogenic form...
-
Clinical significance of focal ß-amyloid deposition measured by 18F-flutemetamol PET
BackgroundAlthough amyloid PET of typical Alzheimer’s disease (AD) shows diffuse ß-amyloid (Aß) deposition, some patients show focal deposition. The...
-
Genistein effect on cognition in prodromal Alzheimer’s disease patients. The GENIAL clinical trial
BackgroundDelaying the transition from minimal cognitive impairment to Alzheimer’s dementia is a major concern in Alzheimer’s disease (AD)...
-
Associations between sex, body mass index and the individual microglial response in Alzheimer’s disease
Background and objectives18-kDa translocator protein position-emission-tomography (TSPO-PET) imaging emerged for in vivo assessment of...
-
Development and clinical validation of CT-based regional modified Centiloid method for amyloid PET
BackgroundThe standard Centiloid (CL) method was proposed to harmonize and quantify global 18 F-labeled amyloid beta (Aβ) PET ligands using MRI as an...
-
Plasma oligomer beta-amyloid is associated with disease severity and cerebral amyloid deposition in Alzheimer’s disease spectrum
BackgroundMultimer detection system-oligomeric amyloid-β (MDS-OAβ) is a measure of plasma OAβ, which is associated with Alzheimer’s disease (AD)...
-
Cognitive trajectories of patients with focal ß-amyloid deposition
BackgroundThe presence of ß-amyloid (Aß) in the brain can be identified using amyloid PET. In clinical practice, the amyloid PET is interpreted based...
-
Subjective cognitive decline and anxious/depressive symptoms during the COVID-19 pandemic: what is the role of stress perception, stress resilience, and β-amyloid?
BackgroundThe COVID-19 pandemic may worsen the mental health of people reporting subjective cognitive decline (SCD) and therefore their clinical...
-
Cognitively unimpaired individuals with a low burden of Aβ pathology have a distinct CSF biomarker profile
BackgroundUnderstanding the changes that occur in the transitional stage between absent and overt amyloid-β (Aβ) pathology within the Alzheimer’s continuum...
-
Baseline cognition is the best predictor of 4-year cognitive change in cognitively intact older adults
BackgroundWe examined in cognitively intact older adults the relative weight of cognitive, genetic, structural and amyloid brain imaging variables...
-
Distinct effects of cholesterol profile components on amyloid and vascular burdens
BackgroundCholesterol plays important roles in β-amyloid (Aβ) metabolism and atherosclerosis. However, the relationships of plasma cholesterol levels...
-
Effects of long-term sleep disruption on cognitive function and brain amyloid-β burden: a case-control study
BackgroundRecent evidence indicates that disrupted sleep could contribute to the development of Alzheimer’s disease by influencing the production...
-
Infrequent false positive [18F]flutemetamol PET signal is resolved by combined histological assessment of neuritic and diffuse plaques
BackgroundThe performance of [ 18 F]flutemetamol amyloid PET against histopathological standards of truth was the subject of our recent article in Alzhe...
-
Assessment of brain beta-amyloid deposition in transgenic mouse models of Alzheimer’s disease with PET imaging agents 18F-flutemetamol and 18F-florbetaben
BackgroundAlthough amyloid beta (Aβ) imaging is widely used for diagnosing and monitoring Alzheimer’s disease in clinical fields, paralleling...
-
International Nuclear Medicine Consensus on the Clinical Use of Amyloid Positron Emission Tomography in Alzheimer’s Disease
Alzheimer’s disease (AD) is the main cause of dementia, with its diagnosis and management remaining challenging. Amyloid positron emission tomography...
-
The effects of imaging markers on clinical trajectory in cerebral amyloid angiopathy: a longitudinal study in a memory clinic
BackgroundWe investigated the relevance of various imaging markers for the clinical trajectory of cerebral amyloid angiopathy (CAA) patients in a...
-
Mild behavioral impairment in early Alzheimer’s disease and its association with APOE and BDNF risk genetic polymorphisms
BackgroundMild behavioral impairment (MBI) has been commonly reported in early Alzheimer’s disease (AD) but rarely using biomarker-defined samples....
-
Gender-specific relationship between thigh muscle and fat mass and brain amyloid-β positivity
BackgroundThe relationship of specific body composition in the thighs and brain amyloid-beta (Aβ) deposition remained unclear, although there were...
